Correspondence 0001493152-23-010069 from CytoMed Therapeutics Ltd (GDTC)
CytoMed Therapeutics Ltd
Date: March 31, 2023 · CIK: 0001873093 · Accession: 0001493152-23-010069
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268456
Letter
Re: CytoMed Therapeutics Limited (the “Company”)
March 31, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, NE
Washington, D.C. 20549
Attn: Tracie Mariner
Registration Statement on Form F-1
File No. 333-268456
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), The Benchmark Company, LLC, as representative of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above referenced registration statement to become effective on Friday, March 31, 2023, at 5:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
[Signature Page Follows]
- 1 -
Securities and Exchange Commission, p. 2
March 31, 2023
Very truly yours,
The Benchmark Company, LLC
Show Raw Text
CORRESP
1
filename1.htm
March
31, 2023
Via
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, NE
Washington, D.C. 20549
Attn:
Tracie Mariner
Re:
CytoMed Therapeutics Limited (the “Company”)
Registration Statement on Form F-1
File No. 333-268456
Ladies
and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), The Benchmark Company, LLC,
as representative of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the
“Commission”) take appropriate action to cause the above referenced registration statement to become effective
on Friday, March 31, 2023, at 5:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter.
Pursuant
to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus,
to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We
have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities
Exchange Act of 1934, as amended, to the extent applicable.
[Signature
Page Follows]
- 1 -
Securities and Exchange Commission, p. 2
March 31, 2023
Very truly yours,
The Benchmark Company, LLC
By:
/s/ John J. Borer III
Name:
John J. Borer III
Title:
Senior Managing Director
cc:
CHOO Chee Kong, CytoMed Therapeutics Limited
Richard A. Friedman, Sheppard, Mullin, Richter &
Hampton LLP
Richard I Anslow, Ellenoff Grossman & Schole LLP
- 2 -